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ABSTRACT 
 
Introduction: Negative symptoms associated with cognitive impairment as a core symptom of 
schizophrenia with significant poor quality of life and remain an unmet clinical need. Administration 
of N-methyl-D-aspartate (NMDA) receptor antagonists in rodents has been proposed as an animal 
model of negative symptoms in this disorder. Evidence from both animal models and human 
studies implicates a dysfunction of NMDA receptor function may attribute to pathophysiology of 
schizophrenia.  
Objectives: This study was undertaken to investigate the ability of sub-chronic co-administration 
of clozapine and haloperidol to both prevent and attenuate the social deficits induced by the NMDA 
receptor antagonist, phencyclidine (PCP) in the social interaction tasks.  
Methods: In the first test, female Sprague-Dawley rats were treated with saline, clozapine 5.0 
mg/kg or haloperidol 0.05 mg/kg, 30 min later followed by either saline or PCP 2.0 mg/kg twice 
daily for 7 days, followed by 7 days drug free before tested in social interaction tasks. For the 
second test, female Sprague-Dawley rats received either vehicle or PCP 2.0 mg/kg for 7 days 
followed by 7 days drug free. Then rats received clozapine 5.0 mg/kg, haloperidol 0.05 mg/kg or 
vehicle twice daily for 7 days and were tested 120 min following the last dose of antipsychotic in 
social interaction tasks.  
Results: PCP treatment produced a significantly reduced social behaviours and that effect 
significantly prevented and improved by clozapine, but not haloperidol.  
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Conclusions: These results suggest that antagonism of the consequences of reduced NMDA 
receptor function could contribute to the superior efficacy of atypical antipsychotic agents in 
improving negative symptoms in schizophrenia. These negative symptoms impairment likely reflect 
clinically relevant and can be used to evaluate the antipsychotic potential of new compounds on 
cognitive symptoms of schizophrenia. 
 
 
Keywords: PCP; negative symptoms; schizophrenia; NMDA receptors; rats. 
 
1. INTRODUCTION 
 
The psychopathology mechanisms underlying 
social withdrawal symptoms of schizophrenia 
associated with and cognitive dysfunction, are 
not clear. Recent studies suggest an implicate of 
the hypofunction of the N-methyl-D-aspartate 
(NMDA) in the pathophysiology of schizophrenia, 
reduced activation of the NMDA receptor subtype 
may play a major role in negative symptoms and 
cognitive dysfunction associated with 
schizophrenia [1-3]. Negative symptoms and 
cognitive dysfunction are considered the most 
significant factor contributing to cause of chronic 
disability in schizophrenia [1,4,3,5,6] and 
specifically suggests treatment-resistant disease 
[7,8]. Thus, there is a need to understand the 
pathophysiology of negative and translate this 
knowledge into new therapies. We used 
pharmacological and behavioural experiments to 
investigate the role of the NMDA receptor 
dysfunction in social withdrawal induced by sub-
chronic phencyclidine (PCP) administration. 
Drugs with N-methyl-D-aspartate receptor 
(NMDAR) antagonist properties, such as 
phencyclidine (PCP) in rodents has been widely 
used to model mimic the symptoms of 
schizophrenia in healthy human subjects [1,4, 3]. 
Previous studies showed that systemic 
administration of atypical but not classical 
antipsychotics attenuated the cognitive deficit 
social withdrawal produced by subchronic PCP 
treatment [9,3,10]. There are number of 
important issues that arise from inspection of the 
work reviewed above although the evidence 
seems almost overwhelming in favour of the use 
of NMDA antagonists to mimic some aspects of 
negative symptoms in rodents along with 
associated neuropathological changes. Atypical 
antipsychotic drugs (APDs) have been found, in 
some [11,5] but not all [7] studies, to have 
modest advantages over typical APDs, such as 
haloperidol, to improve overall behavioural 
function. This highlights the need for continued 
efforts to develop superior therapeutic agents 
with better efficacy to improve negative 
symptoms associated with schizophrenia. A 
mechanism, which could clarify in part, the 
symptomatology and natural course of 
schizophrenia, was proposed, based on NMDA 
receptor hypofunction by Olney and Farber [12]. 
It suggested a dysfunction of the NMDA receptor, 
which could be reproduced by blocking NMDA 
receptors pharmacologically with PCP. Since 
clozapine, but not haloperidol, improves an 
established and enduring deficit induced by sub-
chronic PCP in the other behavioural test, a 
comparison of their effects will assist our 
understanding of the mechanism by which PCP 
induces social behaviour. Specifically, we aimed 
to determine whether chronic daily injections of 
clozapine or haloperidol could affect the ability of 
the potent and selective NMDA antagonist, PCP, 
to produce social behaviour. It has been 
proposed that blocking NMDA receptors with 
PCP also induces excessive release of 
glutamate [13-15] leading to neurotoxicity in the 
rat cortex [16,12]. In addition, it has been 
suggested that sub-chronic PCP treatment can 
be used to produce behaviour deficits in the rat 
which may mimic certain aspects of negative 
symptoms of schizophrenia [17,18,10]. 
Moreover, several hypotheses have been put 
forward to explain the mechanisms of negative 
symptom-like behavioural changes induced by 
PCP. One of the more widely accepted 
propositions is that of a disturbance in dopamine- 
and serotonin-mediated neurotransmission 
[19,11]. The main evidence for this theory is 
derived from the efficacy of 5-HT2A-D2 
antagonists such as clozapine to improve 
negative symptoms. Therefore, clozapine and 
haloperidol were given simultaneously with sub-
chronic PCP in an attempt to reduce the                    
NMDA antagonist effects and alleviate                               
the social withdrawal. Furthermore, the aim of 
this study was to compare the ability of sub-
chronic clozapine and haloperidol to both prevent 
and attenuate the social behaviour deficits 
induced by PCP in in animal models of 
schizophrenia. Such work could provide 
important new information, to support previous 
behavioural studies and further strengthen the 
validity of PCP as a useful pharmacological tool 
to model some of the symptoms of 
schizophrenia. 
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2. MATERIALS AND METHODS 
 
2.1 Social Interaction 
 
The study design was adapted from that 
described by Sams-Dodd [18], Lee et al. [20] and 
Snigdha and Neill [10]. Behaviours are 
represented as three separate measures in this 
study. 
 
2.2 Subjects and Housing Conditions 
 
160Female Sprague-Dawley weighing 240 ± 15 
g were used as subjects. Rats were housed in 
groups of 5 (cages measured 38 cm × 59 cm × 
24 cm) and kept under standard laboratory 
conditions on a 12 h light: dark cycle, lights on at 
07:00 h. Temperature and humidity conditions 
were 21±2°C and 40–50%, respectively. All 
testing was carried out in the light phase. Food 
and water were available. All experiments were 
approved by Animal Experimentation and Ethics 
Committee of University College Cork. 
 
2.3 Apparatus and Objects 
 
The social behaviour test was performed in an 
open-field comprising a square box made of 
opaque Plexiglas (52 cm × 52 cm × 31 cm) 
placed 27 cm above the floor on a moveable 
trolley. The floor of the box was white with black 
gridlines forming nine identical squares. All other 
walls were black. A video camera connected to a 
video recorder and monitor was positioned above 
the box. The object(s) used for the test consisted 
of a heavy structure made of wood or metal that 
could not be displaced by the animals. This was 
done with a view to ascertain that any deficits in 
interactive behaviour such as sniffing and 
climbing over and under observed in this study 
were relevant and specific to the social context 
since object interaction represents interaction 
with an inanimate object. Care was taken to 
ensure that these objects did not have natural 
significance for the rats. 
 
2.4 Testing 
 
The rats were habituated to the test environment 
and arena prior to the test day. Habituation 
consisted of placing all rats from one cage 
together in the empty test arena for 1 h, on the 
day before the test day (day 1). On the test day 
pairs of rats, unfamiliar to each other, receiving 
either the same treatment (vehicle and 
vehicle; n = 10 pairs per group) or different 
treatments (vehicle and PCP; n = 10 pairs per 
group or vehicle and PCP + Drug treatment; 
n = 10 pairs per group) were placed in the test 
arena together for 10 min as described below. An 
inanimate object can was placed in the centre of 
the arena for all trials to measure any differences 
in interaction of the test animal with an unfamiliar 
animal as opposed to an unfamiliar object, as 
described by Snigdha and Neill [10]. After each 
10-min trial, the object and arena were cleaned 
with 10% alcohol in an attempt to remove traces 
of any olfactory cues. All testing was carried out 
under standard room illumination levels 
(70 cd/m2). 
 
2.5 Data Collection 
 
Behaviour in both trials was recorded on video 
for subsequent blind scoring. A behavioural 
scoring software program (Hindsight, Scientific 
Programming Services) was used to score the 
following five parameters: 
 
Following: rat moves after the conspecific around 
the arena. 
 
Investigative sniffing behaviour: sniffing the 
conspecific's snout or parts of the body. 
 
Avoiding: actively turning away or freezing when 
approached by the conspecific animal. 
 
Previous studies revealed that there were no 
instances of threatening behaviour or biting 
(termed aggression) in weight matched 
unfamiliar animals placed in the arena; 
aggression was hence excluded from the set of 
behavioural criteria used here. 
 
2.6 Drug Treatment and Preparation 
 
In the first test (Prevention), following the 
habituation period, female Sprague-Dawley rats 
were treated with saline, clozapine 5.0 mg/kg or 
haloperidol 0.05 mg/kg, 30 min later followed by 
either saline or PCP 2.0 mg/kg twice daily for 
seven days, followed by seven days drug free 
before tested in social interaction task. For the 
second test(Reversal), female Sprague-Dawley 
rats received either vehicle or PCP 2.0 mg/kg for 
seven days followed by seven days drug free. 
Then rats received clozapine 5.0 mg/kg, 
haloperidol 0.05 mg/kg or vehicle twice daily for 
seven days and were tested 120 min following 
the last dose of antipsychotic in social task. The 
PCP dosing regimen was based on previous 
study [21,22]. This dose of clozapine has been 
shown to reverse a acute and sub-chronic [21-
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24], PCP-induced cognitive deficit. An identical 
dose of haloperidol improved an acute d-
amphetamine-, but not PCP-induced cognitive 
deficit acute in the rats [25]. Following drug 
treatment, the animals were given a one-week 
drug free period prior to social interaction task. 
This was based on a previous study [23,24], 
which suggested that at least a 1-week period of 
withdrawal was necessary to avoid behaviour 
being influenced by any residual drug effects. 
Drug doses were calculated as the base 
equivalent weight. PCP HCL was dissolved in 
0.9% saline; clozapine was dissolved in a 
minimum volume of acetic acid, made up to 
volume with 0.9% saline and pH adjusted to 6 
with 0.1 M NaOH. Haloperidol was prepared in 
saline.  
 
2.7 Statistical Analysis  
 
All data are expressed as mean ± S.E.M. (n = 10 
pairs per group). Social Interaction: Data were 
analysed by a factorial one-way ANOVA. This 
detected the effect of drug treatment on each 
behaviour set observed during the test. Further 
analysis by a post hoc unpaired t-test was 
carried out, where appropriate, to compare 
individual group means. Attentional Set-Shifting 
Test: Trials to criterion, errors to criterion, and 
correct and incorrect response times were 
recorded for every rat at each stage. A paired 
Student’s t-test was carried out to compare 
difficulty between phases within the same 
treatment group and compare between treatment 
groups within the same phase. 
 
3. RESULTS 
 
Experiment 1: The influence of 7 days co-
administration of clozapine and haloperidol with 
PCP (Prevention). As can be seen from Figs. 1-
3, co-administration of clozapine but not 
haloperidol completely prevented the disruptive 
effect of PCP on social behaviours. Detailed 
analysis using unpaired t-tests showed that co-
administration of clozapine significantly 
prevented the PCP-induced reduction in the 
normal explorative sniffing and following 
behaviours (p < 0.001) which was significantly 
reduced in PCP-treated animals (p < 0.001), 
Figs. 1-2. A significant effect was also observed 
on avoiding behaviours with the clozapine 
treated animals spending significantly less time 
avoiding the conspecific compared to the PCP 
group (p < 0.001). In contrast, co-administration 
of haloperidol had no significant effect to                 
prevent any social behaviour deficits induced by 
PCP). 
Experiment 2: The influence of 7 days 
administration of clozapine and haloperidol on 
sub-chronic PCP-induced Cognitive Deficit 
(Reversal). Detailed analysis using unpaired t-
tests showed that sub-chronic treatment with 
clozapine restored the normal explorative sniffing 
and following behaviours (p < 0.001) which was 
significantly reduced in PCP-treated animals (p < 
0.001). A significant effect was also observed on 
avoiding behaviours with the clozapine treated 
animals spending significantly less time avoiding 
the conspecific compared to the PCP group (p < 
0.001), whereas the D2 receptor antagonist 
haloperidol treatment with failed to restore any 
social behaviour deficits induced by PCP. 
 
4. DISCUSSION  
 
This study confirms that sub-chronic PCP 
treatment produces robust social behaviour 
deficits in female rats. The main findings of this 
study the social behaviours reduction induced by 
PCP were prevented by pre-treatment with 
clozapine, but not haloperidol. This is the first 
demonstration of the preventive effect of an 
atypical APD clozapine on subchronic PCP-
induced disruption in social behaviours in rats. 
We also found that the effect of clozapine 
improved the social behaviours deficits induced 
by PCP in social behaviours tasks. It has been 
suggested that sub-chronic PCP treatment can 
be used to produce behaviour deficits in the rat 
which may mimic certain aspects of negative 
symptoms of schizophrenia [17,26] and [10]. 
Moreover, several hypotheses have been put 
forward to explain the mechanisms of negative 
symptom-like behavioural changes induced by 
PCP. One of the more widely accepted 
propositions is that of a disturbance in dopamine- 
and serotonin-mediated neurotransmission 
[9,19]. The main evidence for this theory is 
derived from the efficacy of 5-HT2A-D2 
antagonists such as risperidone and clozapine to 
improve negative symptoms. However recently, 
some data contradicting this hypothesis has 
been emerging [7,10]. Furthermore, some recent 
data also throw light on the more active role of 5-
HT1A receptor activation in modulating 
glutamatergic dysfunction observed in 
schizophrenia and in animal models of the 
disease. Glutamate release is decreased by 5-
HT1A activation [27]. and evidence of a 5-
HT1A/glutamatergic interaction has also been 
described at the neuroendocrine level [28]. The 
mechanism(s) underlying the consequence of the 
NMDA hypofunction state in humans, several 
lines of evidence suggest that a large number of 
  
 
 
Idris; INDJ, 9(3): 1-10, 2017; Article no.INDJ.34161 
 
 
 
5 
 
these drug-induced effects are dose-dependent 
manifestations of the same general disinhibition 
process in which NMDA antagonists abolish 
GABAergic inhibition, resulting in the 
simultaneous excessive release of                    
acetylcholine and glutamate [15,29]. Progressive 
increases in the severity of NMDA receptor 
hypofunction within the brain produce an 
increasing range of effects on brain function, 
which may contribute to psychosis in 
schizophrenia [15,12]. 
 
Clozapine improved the reversal learning deficit 
induced by PCP, without affecting the similar 
deficit of the reversal learning task produced by 
the dopamine releaser amphetamine [14,25] 
Clozapine has a complex pharmacology that 
includes indirect interactions with NMDA 
receptors [20,30], as well as direct interaction 
with a range of neurotransmitter receptors, 
including dopamine, serotonin and acetylcholine 
[31,3,32,33]. However, antagonism of 5-HT2A 
receptors, which positively regulate glutamate 
release in the cortex, has also been suggested to 
be important for antipsychotic efficacy [33-
36,27,9,19,11,5]. Thus, the effect of clozapine 
has been attributed in part to 5-HT2A effects 
[31,13], because blockade of these receptors
 
 
 
Fig. 1. The influence of sub-chronic co-administration of clozapine (5.0 mg/kg) or haloperidol 
(0.05 mg/kg) followed by treatment with vehicle or PCP on following duration of the social 
interaction task 
Data are shown as mean ± s.e.m. duration ms (n=10). Significant reduction in following duration of the social 
interaction compared with the vehicle group; ***P<0.001. Significant improvement in following duration compared 
to PCP alone # # # P<0.001, ANOVA followed by LSD t- test 
 
 
 
Fig. 2. The influence of sub-chronic co-administration of clozapine (5.0 mg/kg) or haloperidol 
(0.05 mg/kg) followed by treatment with vehicle or PCP on sniffing duration of the social 
interaction task 
Data are shown as mean ± s.e.m. duration ms (n=10). Significant reduction in following duration of the social 
interaction compared with the vehicle group; ***P<0.001. Significant improvement in following duration compared 
to PCP alone # # # P<0.001, ANOVA followed by LSD t- test 
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Fig. 3. The influence of sub-chronic co-administration of clozapine (5.0 mg/kg) or haloperidol 
(0.05 mg/kg) followed by treatment with vehicle or PCP on sniffing duration of the social 
interaction task 
Data are shown as mean ± s.e.m. duration ms (n=10). on avoiding duration of the social interaction task. Data 
are shown as mean ± s.e.m. duration ms (n=10). Significant increase in avoiding duration of the social interaction 
compared with the vehicle group; ***P<0.001. Significant decrease in avoiding duration compared to PCP alone # 
# # P<0.001, ANOVA followed by LSD t- test 
 
 
 
Fig. 4. The effect of sub-chronic administration of clozapine (5 mg/kg) or haloperidol (0.05 
mg/kg) on the PCP-induced deficit on following duration of the social interaction task 
Data are shown as mean ± s.e.m. duration ms (n=10). Significant reduction in following duration of the social 
interaction compared with the vehicle group; ***P<0.001. Significant improvement in following duration compared 
to PCP alone # # # P<0.001, ANOVA followed by LSD t- test 
 
might be expected to reduce glutamate release 
associated with PCP [32]. The idea that PCP 
induced glutamate activation may be secondary 
to activation of 5-HT2A receptors is consistent 
with results of studies suggesting that some of 
the behavioural and dopaminergic effects of PCP 
and other NMDA antagonists in the rodent are 
attenuated by the selective 5-HT2A antagonist, 
M100907 [35-38]. In addition, prefrontal cortex 
has also been implicated in playing a role in 
social interaction in particular is innervated by a 
prominent dopaminergic projection [34,6,39] and 
there are several pharmacological interventions 
which can modulate DA release in the prefrontal 
cortex. Dopamine D2 and serotonin 5-HT2A 
receptor antagonism by clozapine, increases the 
effect of 5-HT1A receptor activation on DA 
release in the prefrontal cortex [40]. Selective 5-
HT1A receptor agonists, increase DA release in 
the prefrontal cortex. [41], suggesting that 5-
HT1A induced DA release in the prefrontal cortex 
may be the potential basis for mechanism of 
action of Clozapine. Furthermore, ability o of 
Clozapine to increase DA release in the 
prefrontal cortex is blocked by WAY100635, a 5-
HT1A receptor antagonist [42]. Together with 
previous findings regarding the beneficial effects 
of clozpine but not haloperidol on
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Fig. 5. The effect of sub-chronic administration of clozapine (5 mg/kg) or haloperidol (0.05 
mg/kg) on the PCP-induced deficit on sniffing duration of the social interaction task 
Data are shown as mean ± s.e.m. duration ms (n=10). Significant reduction in following duration of the social 
interaction compared with the vehicle group; ***P<0.001. Significant improvement in following duration compared 
to PCP alone # # # P<0.001, ANOVA followed by LSD t- test. 
 
 
 
Fig. 6. The effect of sub-chronic administration of clozapine (5 mg/kg) or haloperidol (0.05 
mg/kg) on the PCP-induced deficit on sniffing duration of the social interaction task 
Data are shown as mean ± s.e.m. duration ms (n=10). on avoiding duration of the social interaction task. Data 
are shown as mean ± s.e.m. duration ms (n=10). Significant increase in avoiding duration of the social interaction 
compared with the vehicle group; ***P<0.001. Significant decrease in avoiding duration compared to PCP alone # 
# # P<0.001, ANOVA followed by LSD t- test
 
PCP-induced social behaviour deficits, these 
findings support the hypothesis that                         
partial agonism at 5-HT1A receptors has an 
important role in improving the negative 
symptom. 
 
5. CONCLUSION 
 
These results suggest that antagonism of the 
consequences of reduced NMDA receptor 
function could contribute to the superior efficacy 
of atypical antipsychotic agents in improving 
negative symptoms in schizophrenia. These 
negative symptoms likely reflect clinically 
relevant and can be potential new targets for the 
development of new antipsychotics with a broad 
spectrum in the treatment of negative symptoms 
in schizophrenia. 
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